Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Gedde-Dahl, Tobias  [Clear All Filters]
2013
Mellqvist U-H, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase III trial. Blood. 2013.
2015
Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S. Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning. Ther Drug Monit. 2015.
2019
Søraas A, Matsuyama M, de Lima M, Wald D, Buechner J, Gedde-Dahl T, Søraas CLund, Chen B, Ferrucci L, Dahl JArne, et al. Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells. Aging Cell. 2019:e12897.
Tvedt THenrik And, Skaarud KJ, Tjønnfjord GErland, Gedde-Dahl T, Iversen POle, Bruserud Ø. THE SYSTEMIC METABOLIC PROFILE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: EFFECTS OF ADEQUATE ENERGY SUPPORT ADMINISTERED THROUGH ENTERAL FEEDING TUBE. Biol Blood Marrow Transplant. 2019.
2020
Divito SJ, Aasebo AT, Matos TR, Hsieh P-C, Collin M, Elco CP, O'Malley JT, Bækkevold ES, Reims HM, Gedde-Dahl T, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. J Clin Invest. 2020.
2021
Andersen AMikal, Bergan S, Gedde-Dahl T, Buechner J, Vethe NTore. Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients. J Pharm Biomed Anal. 2021;203:114216.
Cesaro S, Tridello G, Knelange NSimone, Blijlevens N, Martin M, Snowden JA, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T, et al. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. Bone Marrow Transplant. 2021.